Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2020-001681
Abstract: Background To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab. Methods The study was divided into…
read more here.
Keywords:
part;
eftilagimod alpha;
lymphocyte activation;
patients metastatic ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0790
Abstract: Background Eftilagimod alpha (efti) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell (APC) and CD8 T-cell activation. The stimulation of the dendritic cell…
read more here.
Keywords:
lag protein;
eftilagimod alpha;
study;
soluble lag ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.3099
Abstract: 3099Background: Stratum D of the INSIGHT study investigates the feasibility and safety of s.c. application of IMP321 (eftilagimod alpha) combined with the PD-L1 inhibitor avelumab in advanced stage...
read more here.
Keywords:
stratum insight;
eftilagimod alpha;
feasibility safety;
alpha combined ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.3100
Abstract: 3100Background: Eftilagimod alpha (efti) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell (APC) activation and then CD8 T-cell activati...
read more here.
Keywords:
lag protein;
soluble lag;
cell;
eftilagimod alpha ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.6028
Abstract: 6028 Background: Eftilagimod alpha (efti) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell (APC) activation and CD8 T-cell activation. The stimulation of the…
read more here.
Keywords:
eftilagimod alpha;
lag protein;
pembrolizumab;
study ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Future oncology"
DOI: 10.2217/fon-2018-0807
Abstract: Eftilagimod alpha (IMP321), a soluble dimeric recombinant form of LAG-3, is a first-in-class antigen presenting cell activator under clinical development. By stimulating dendritic cells through MHC class II molecules, IMP321 was proven to induce sustained…
read more here.
Keywords:
metastatic breast;
alpha imp321;
eftilagimod alpha;
breast cancer ... See more keywords